NICE Javlor ''torture'' could have international ripple effect
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has again decided that there is not enough conclusive evidence to recommend Pierre Fabre's Javlor (vinflunine) for treating bladder cancer after prior platinum treatment has failed. The decision is a disaster and other markets as far afield as Mexico could take up the decision too, said Martin Grange, Pierre Fabre's UK managing director. "The impact NICE has on the world is devastating," he said.